Mereo BioPharma (MREO) Accounts Payables (2017 - 2026)

Mereo BioPharma (MREO) has 10 years of Accounts Payables data on file, last reported at $3.2 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $3.2 million, up 10.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 million (up 10.33% YoY), and the FY2025 annual result was $1.3 million, down 45.37% from the prior year.
• Accounts Payables grew to $3.2 million in Q1 2026 per MREO's latest filing, from $1.3 million in the prior quarter.
• Over five years, Accounts Payables peaked at $3.6 million in Q4 2022 and troughed at $879000.0 in Q3 2025.
• A 5-year average of $2.3 million and a median of $2.4 million in 2024 frame the typical range for Accounts Payables.
• On a YoY basis, Accounts Payables climbed as much as 19.1% in 2025 and fell as far as 57.85% in 2025.
• A 5-year view of Accounts Payables shows it stood at $3.6 million in 2022, then slumped by 35.02% to $2.3 million in 2023, then rose by 4.01% to $2.4 million in 2024, then tumbled by 45.37% to $1.3 million in 2025, then jumped by 142.01% to $3.2 million in 2026.
• Business Quant data shows MREO's Accounts Payables at $3.2 million in Q1 2026, $1.3 million in Q4 2025, and $879000.0 in Q3 2025.